UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) February 24, 2005

THE QUIGLEY CORPORATION

(Exact Name of Registrant as Specified in Charter)

Nevada	0-21617	23-2577138
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Kells Building, 621 Shady Retreat Road, P.O. Box 1349, Doylestown, PA 18901
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code (215) 345-0919

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On February 24, 2005, The Quigley Corporation (the "Company") issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2004. The full text of the press release is attached hereto as Exhibit 99.1.

The information furnished pursuant to Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be considered "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of such section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended or under the Securities Exchange Act of 1934, as amended, unless the Company expressly sets forth in such future filing that such information is to be considered "filed" or incorporated by reference therein.

ITEM 8.01 OTHER EVENTS.

On February 24, 2005, the Company issued a press release providing updates on the status of its pharmaceutical pipeline. The full text of the press

release is attached hereto as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

Exhibit No.	Description
99.1	Press Release dated February 24, 2005 reporting fourth quarter and fiscal year ended December 31, 2004 preliminary unaudited earnings and updates on the status of the Company's pharmaceutical pipeline.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE QUIGLEY CORPORATION
(Registrant)

Date: February 24, 2005

By: /s/ George J. Longo

Name: George J. Longo
Title: Vice President and Chief Financial Officer

EXHIBIT 99.1

QUGILEY

CONTACT:

Carl Hymans
G.S. Schwartz & Co.
(212) 725-4500
carlh@schwartz.com

Carl Fonash
The Quigley Corporation
(267) 880-1111
fonash@quigleyco.com

QUIGLEY INCREASES REVENUES FOR THE FOURTH QUARTER AND FISCAL YEAR

- PROFITABILITY CONTINUES IN 2004 WHILE INVESTING $3.2 MILLION IN R&D -

DOYLESTOWN, PA. - FEBRUARY 24, 2005 - THE QUIGLEY CORPORATION (NASDAQ: QGLY) today reported net sales of $17.8 million, an increase of 8.3%, for the fourth quarter ended December 31, 2004, compared to $16.4 million reported for the same period in 2003. For the year ended December 31, 2004, net sales were $43.9 million, an increase of 5.9%, compared to $41.5 million in 2003.

Net sales of the Company's Cold Remedy segment increased 10.1% for the fourth quarter of 2004 as compared to 2003. Net sales of the Health and Wellness segment decreased 9.4% during the quarter, due to a decline in the number of active domestic independent representatives, which was partially offset by an increase of 14.1% in this segment's European sales as compared to 2003.

The increase in net sales for the year ended December 31, 2004 reflects an 11.5% increase in the Company's Cold Remedy segment and also reflects a 3.2% decrease in net sales for the Health and Wellness segment, which were offset by this segment's gains in international distribution of 135.4%. Even though the incidence of colds during 2004 were fewer than the previous year, the Company's Cold Remedy net sales increase for the year ended December 31, 2004 reflects the success of expanded targeted advertising, marketing initiatives and new product extensions of COLD-EEZE(R), which have generated greater consumer awareness and purchasing of our products.

Net income for the fourth quarter ended December 31, 2004 was $2.0 million, or $0.13 per share, compared to net income of $2.5 million, or $0.17 per share, for the same period last year. Net income for the year ended December 31, 2004 was $453,000, or $0.03 per share, compared to a net income of $675,000, or $0.05 per share, for the same period last year. During the fourth quarter and year ended December 31, 2004, the Company incurred research and development costs of $837,000 and $3.2 million, respectively, as compared to $766,000 and $3.4 million, for the comparable periods of 2003. Additionally, net income margins by segments for the year 2004 are relatively consistent with net income margins attained in 2003.

Gross profit margins for the quarter and year ended December 31, 2004 remained relatively unchanged as compared with the same periods last year. Net income for the fourth quarter and year ended December 31, 2004 were primarily driven by profit gains from the increased sales, which were offset by an increase of $1.0 million in advertising costs. The fiscal year results were also affected by a $178,000 increase in other income, which was offset by a charge to gross profit margins of $1.4 million, or $0.09 per share, related to the discontinuation of the Company's COLD-EEZE(R) Cold Remedy Nasal Spray product. This charge includes a $672,000 write-off of nasal spray inventory and a $680,000 reduction to net sales resulting from anticipated customer returns of the product.

No tax or tax benefits to reduce income or losses are provided for the quarters and year ended December 31, 2004 and 2003, since the Company is in a net operating loss carry-forward position, which is from the cumulative effect of deductions attributed to options, warrants and unrestricted stock from previous years' taxable income.

On October 1, 2004, the Company acquired the assets of JoEL, Inc., encompassing inventory, land, buildings, machinery and equipment of two manufacturing facilities, located in Lebanon and Elizabethtown, Pennsylvania for approximately $5.1 million. The facilities are FDA approved and have been the exclusive manufacturing sites of the Company's COLD-EEZE(R) lozenge since its launch in 1995. The purchase of the manufacturing facilities allowed for the establishment of Quigley Manufacturing Inc., which protects the proprietary manufacturing process of COLD-EEZE(R) and is anticipated to improve cost efficiencies as volume production increases and allow for the manufacture of other brands.

Guy J. Quigley, Chairman, President and Chief Executive Officer stated, "We are pleased with our results for 2004 which reflect increased sales of our core products and greater market penetration of our COLD-EEZE(R) Cold Remedy products which enabled us to further fund pharmaceutical research and development. In

addition to increasing annual revenue, gross margins for the year would have increased without the previously mentioned $1.4 million one-time costs associated with a product discontinuation.

"We expect that our recently introduced new or improved products including COLD-EEZE(R) Bubble Gum and COLD-EEZE(R) 'Green-Tea with honey' lozenges will garner greater consumer acceptance and enhance product sales. We will continue to develop products that appeal to adults as well as a younger demographic, which could represent a significant opportunity for expansion in market penetration and future growth.

"The main core of our Health and Wellness Company, our Supergreens(TM) line of products developed by Dr. Robert O. and Shelley Redford Young, continues to move forward with loyal distributors. The Company is also excited by the launch of an exclusive skin care line under the BEVERLY SASSOON brand name to diversify this segment's product offerings.

"We also remain focused on expanding our wholly-owned Ethical Pharmaceuticals subsidiary, Quigley Pharma, which is developing natural-source prescription medicinals for Diabetic Neuropathy, Systemic Radiation, Influenza A, and Rheumatoid Arthritis. We continue moving forward with our development and testing phases of ethical pharmaceutical drugs and are confident that this segment of our business will be a source of future growth for the Company," concluded Mr. Quigley.

The following is a list of formulations currently in the Quigley Pharm pipeline and an update on their progress:

DIABETIC NEUROPATHY -- QR 333: Per the FDA's instructions at the last Pre-IND Meeting for the continued development of this drug; the compound is undergoing a series of toxicity studies to support the safety of this naturally derived compound for the relief of symptoms of diabetic peripheral neuropathy, prior to beginning a human Phase IIB dose ranging study. The company expects the toxicity studies to be completed by June 2005. The company hopes to begin pivotal studies on this compound in 2005.

SYSTEMIC RADIATION -- QR336: There were encouraging results seen in a preliminary non-GLP animal study of this naturally derived radio protective compound against ionizing radiation. A pre-IND meeting was held at the FDA in October of 2004 with the Division of Medical Imaging and Radiopharmaceutical Drug Products. A GLP controlled animal study of the QR 336 formulation for the Radioprotection/Treatment of Radiation Lethality Induced by Four MeV Photons in the C3H Mouse will begin this year after a short series of experiments to further define the compound's method of action.

INFLUENZA A -- QR435: Retroscreen LTD. at The University of London has started a final animal model influenza study in preparation for a proposed human Proof Of Concept Study to start in mid-2005. The study "Prophylactic potential of different QR-435 antiviral nasal spray formulations in the Influenza A/Panama/2007/99 (H3N2) virus ferret transmission model" will determine if there is any efficacy or safety issues with different dose forms of this naturally derived broad-spectrum anti-viral compound.

VIRUCIDAL COMPOUND -- QR437: Ongoing pre-clinical research activities include: the completion of a second in vitro experiment to determine virucidal or virustatic properties against the HIV virus by QR437. The results of the first in vitro study determined that this naturally derived compound has significant dose dependant virucidal properties with a probable rapid mode of action. This type of compound might be used with condoms or intravaginal, oral and other topical dose forms as a first line defense against infection. Ongoing plans for this compound are pending; the company expects to announce next steps some time in 2005.

ARTHRITIS COMPOUND - QR-440: Quigley Pharma is also conducting research on its previously announced patented compound for the treatment of rheumatoid arthritis and similar diseases.

AVIAN FLU COMPOUND - QR-441: One positive pre-clinical in vitro study on Avian Flu, demonstrating antiviral activity when tested in a virustatic test. Ongoing plans for this compound are pending; the company expects to announce next steps some time in 2005.

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will grant an Investigational New Drug ("IND") or take any other action to allow its formulations to be studied or marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration. Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound, referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well controlled clinical studies before

the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading developer and marketer of diversified health products including the COLD-EEZE(R) family of patented zinc gluconate glycine (ZIGG(TM)) lozenges and sugar free tablets. COLD-EEZE is the only (ZIGG) lozenge proven in two double-blind studies to reduce the duration of the common cold from 7.6 to 4.4 days or by 42%. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of naturally-derived patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

(Tables Follow)

CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

The following represents condensed financial data (in thousands) except per share data:

	Three-Months Ended December 31, 2004 ($)	Three-Months Ended December 31, 2003 ($)	Year Ended December 31, 2004 ($)	Year Ended December 31, 2003 ($)
Net Sales	17,750	16,391	43,947	41,499
Gross profit	9,278	9,064	20,375	20,011
Sales & marketing expenses	3,767	2,728	7,140	6,166
Administrative expenses	2,701	3,043	9,820	9,844
Research & development	837	766	3,233	3,366
Income taxes (Benefit)	--	--	--	--
Income (Loss) from:				
Continuing operations	1,970	2,542	453	729
Discontinued operations	--	--	--	(54)
Net income	1,970	2,542	453	675
Continuing operations	$0.13	$0.17	$0.03	$0.05
Discontinued operations	--	--	--	--
Net income	$0.13	$0.17	$0.03	$0.05
Diluted weighted average common shares outstanding:	14,602,716	15,036,895	14,449,334	14,910,246

Consolidated Balance Sheets (Unaudited)
- ----------

The following represents condensed financial data (in thousands) at December 31:

	2004 ($)	2003 ($)
Cash & cash equivalents	14,366	11,392
Accounts receivable, net	6,376	7,862
Inventory	3,455	3,753
Total current assets	24,961	23,740
Total assets	31,530	26,270
Total current liabilities	7,109	5,483

Long-term debt	2,464	--
Total stockholders' equity	21,902	20,787